Avricore Health Inc. Files August 2025 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, regulatory-filing, foreign-private-issuer
TL;DR
Avricore Health (AVRX) filed its standard August 6-K, no major news.
AI Summary
Avricore Health Inc. filed a Form 6-K for the month of August 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered in Vancouver, BC. This filing is routine and does not contain specific financial transactions or material events for the period.
Why It Matters
This filing serves as a routine update for investors and regulatory bodies, confirming Avricore Health Inc.'s status as a foreign private issuer and providing basic company information.
Risk Assessment
Risk Level: low — This is a routine filing that does not disclose new material financial information or significant corporate events.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- Vancouver, BC (location) — Principal executive office location
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of August 2025, filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is Avricore Health Inc.'s central index key (CIK)?
Avricore Health Inc.'s central index key is 0001355736.
What is the principal executive office address for Avricore Health Inc.?
The principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Has Avricore Health Inc. changed its name previously?
Yes, Avricore Health Inc. was formerly known as Vanc Pharmaceuticals Inc. (name change 20140911), NUVA Pharmaceuticals Inc. (name change 20140110), and ALDA Pharmaceuticals Corp. (name change 20060309).
Does Avricore Health Inc. file annual reports under Form 20-F or 40-F?
Avricore Health Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 18.5 · Accepted 2025-09-12 18:36:03
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex1.htm (EX-1) — 466KB
- ex2.htm (EX-2) — 312KB
- ex3.htm (EX-3) — 13KB
- ex4.htm (EX-4) — 9KB
- ex1_001.jpg (GRAPHIC) — 5KB
- ex2_001.jpg (GRAPHIC) — 5KB
- 0001493152-25-013298.txt ( ) — 835KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: September 12, 2025 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number